Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296525 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
A Phase 1 study, sponsored by Gamida Cell.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05296525 is a Phase 1 study that was terminated before completion, run by Gamida Cell. The registered enrollment target is 13 participants.
The verdict
NCT05296525, a Phase 1 study, was terminated before completion, sponsored by Gamida Cell.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).
Interventions
- DRUG GDA-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296525
The ClinicalTrials.gov registry entry for NCT05296525 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDA-201 is the first listed.
NCT05296525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05296525 about?
NCT05296525 is a clinical study titled "Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL". This is an open-label, non-randomized, interventional, single group assignment study of GDA-201, an allogeneic cryopreserved Natural Killer (NK) cell therapy derived from donor peripheral blood, in combination with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B ...
What is the current status of trial NCT05296525?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-07-05. Estimated completion is 2024-04-22.
What interventions are being tested in trial NCT05296525?
The interventions under investigation include: GDA-201 (DRUG).
Who is sponsoring clinical trial NCT05296525?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.